重新审视对比增强与非增强肿瘤切除范围对2021年世界卫生组织分类成人型弥漫性胶质瘤生存影响的不同
该回顾性单中心研究纳入1193例成人型弥漫性胶质瘤患者,评估对比增强(CE)和非增强(NE)肿瘤切除范围(EOR)对生存的影响。结果显示在IDH突变型星形细胞瘤和IDH野生型胶质母细胞瘤中,CE和NE肿瘤的全切除(GTR)均与更好生存独立相关;在少突胶质细胞瘤中,仅CE肿瘤的GTR是生存的独立预测因素,而NE肿瘤的GTR与生存无关。
要点
- 在IDH突变型星形细胞瘤和IDH野生型胶质母细胞瘤中,CE和NE肿瘤的GTR均与更好生存独立相关(所有p<0.05)。
- 在少突胶质细胞瘤中,CE肿瘤的GTR是唯一独立生存预测因素(HR=0.56,p=0.223为NE肿瘤GTR结果)。
- 少突胶质细胞瘤中NE肿瘤的GTR与生存无关(HR=0.56,p=0.223),提示积极GTR NE肿瘤可能不必要。
核心结论
- 在IDH突变型星形细胞瘤和IDH野生型胶质母细胞瘤中,CE和NE肿瘤的GTR可能显著改善生存;在少突胶质细胞瘤中,CE肿瘤的EOR对生存可能至关重要,积极GTR NE肿瘤可能不必要,而推荐GTR CE肿瘤。
研究设计与样本
- 回顾性单中心研究,纳入2001年至2021年间诊断的1193例成人型弥漫性胶质瘤患者(183例少突胶质细胞瘤、211例IDH突变型星形细胞瘤、799例IDH野生型胶质母细胞瘤),具备IDH突变、1p/19q共缺失和MGMT状态完整信息,采用Cox生存分析评估各类型内总生存预测因素。
诊断标准与关键数值
- 在全部少突胶质细胞瘤中,NE肿瘤GTR与生存无关(HR=0.56,p=0.223)。
- 在86例(47.0%)伴有CE肿瘤的少突胶质细胞瘤患者中,CE肿瘤GTR是唯一独立生存预测因素(HR=0.16,p=0.004)。
- 在IDH突变型星形细胞瘤和IDH野生型胶质母细胞瘤中,CE和NE肿瘤的GTR均与更好生存独立相关(所有p<0.05)。
临床应用与阅片要点
- 作者建议在少突胶质细胞瘤中推荐GTR CE肿瘤,而积极GTR NE肿瘤可能不必要。
- 在IDH突变型星形细胞瘤和IDH野生型胶质母细胞瘤中,CE和NE肿瘤的GTR可能显著改善生存。
- 手术策略应依据2021年WHO分类的成人型弥漫性胶质瘤类型重新考虑。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: Extent of resection (EOR) of contrast-enhancing (CE) and non-enhancing (NE) tumors may have different impacts on survival according to types of adult-type diffuse gliomas in the molecular era. This study aimed to evaluate the impact of EOR of CE and NE tumors in glioma according to the 2021 World Health Organization classification.
METHODS: This retrospective study included 1193 adult-type diffuse glioma patients diagnosed between 2001 and 2021 (183 oligodendroglioma, 211 isocitrate dehydrogenase [IDH]-mutant astrocytoma, and 799 IDH-wildtype glioblastoma patients) from a single institution. Patients had complete information on IDH mutation, 1p/19q codeletion, and O6-methylguanine-methyltransferase (MGMT) status. Cox survival analyses were performed within each glioma type to assess predictors of overall survival, including clinical, imaging data, histological grade, MGMT status, adjuvant treatment, and EOR of CE and NE tumors. Subgroup analyses were performed in patients with CE tumor.
RESULTS: Among 1193 patients, 935 (78.4%) patients had CE tumors. In entire oligodendrogliomas, gross total resection (GTR) of NE tumor was not associated with survival (HR = 0.56, p = 0.223). In 86 (47.0%) oligodendroglioma patients with CE tumor, GTR of CE tumor was the only independent predictor of survival (HR = 0.16, p = 0.004) in multivariable analysis. GTR of CE and NE tumors was independently associated with better survival in IDH-mutant astrocytoma and IDH-wildtype glioblastoma (all ps < 0.05).
CONCLUSIONS: GTR of both CE and NE tumors may significantly improve survival within IDH-mutant astrocytomas and IDH-wildtype glioblastomas. In oligodendrogliomas, the EOR of CE tumor may be crucial in survival; aggressive GTR of NE tumor may be unnecessary, whereas GTR of the CE tumor is recommended.
CLINICAL RELEVANCE STATEMENT: Surgical strategies on contrast-enhancing (CE) and non-enhancing (NE) tumors should be reassessed considering the different survival outcomes after gross total resection depending on CE and NE tumors in the 2021 World Health Organization classification of adult-type diffuse gliomas.
KEY POINTS: The survival impact of extent of resection of contrast-enhancing (CE) and non-enhancing (NE) tumors was evaluated in adult-type diffuse gliomas. Gross total resection of both CE and NE tumors may improve survival in isocitrate dehydrogenase (IDH)-mutant astrocytomas and IDH-wildtype glioblastomas, while only gross total resection of the CE tumor improves survival in oligodendrogliomas. Surgical strategies should be reconsidered according to types in adult-type diffuse gliomas.
引用
- Park YW, Kim S, Han K, et al. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification. Eur Radiol. 2023. PMID: 37608093. doi:10.1007/s00330-023-10125-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。